人附睾蛋白4检测早期卵巢癌

The Human Epididymis Protein 4 Detection of Early Ovarian Cancer

卵巢癌是威胁女性生命健康的三大生殖道恶性肿瘤之一,其年轻化趋势明显且死亡率高居首位,如何提高卵巢癌患者早期检出率是降低该病死亡率的关键。传统卵巢癌标记物——糖类抗原125(CA125)虽然广泛应用于临床,但是敏感度和特异度较低,并且在一些妇科良性疾病中也出现非特异性的升高,因此迫切需要一种高敏感度和特异度的检测指标。近年来颇受瞩目的血清标记物——人附睾蛋白4(HE4)成为了早期诊断卵巢癌的焦点,相比于CA125,HE4在大多数非卵巢恶性肿瘤中不表达或低表达,并且单独检测HE4或联合CA125在对卵巢癌的早期诊断、疗效和预后评价等方面更具优势,现已在国外和国内多家三甲医院推广应用。现对HE4的发现、发展和临床应用及其与CA125构建的卵巢恶性肿瘤发病风险模型(ROMA)作综述。

Ovarian cancer threatens women＇s lives and health which is one of the three malignant tumors of reproductive tract, its younger trend obvious and mortality rate ranked first. It is a key point to reduce the mortality rate of the patients by improving the detectable rate of the ovarian cancer at early stage. However, the traditional ovarian tumor markers carbohydrate antigen 125 （CA125） which is applied widely, shows a low sensitivity and specificity in ovarian cancer and also appears high level in benign gynecological diseases nonspecifically, therefore, a higher sensitivity and specificity detection index is needed urgently. In recent years, the serum marker human epididymis protein 4 （HE4） has become the focus of the early diagnosis of ovarian cancer. Compared to CA125, HE4 were not expressed in most of the ovarian malignant tumor or low expression, and detection of HE4 alone or combined CA125 in early diagnosis of ovarian cancer, curative effect and prognosis evaluation of an edge. Now HE4 has been applied in foreign and some first-class hospital in China. This paper reviews the discovery of HE4, development and clinical application and ovarian malignant tumor with CA125 constructs the risk of ovarian malignancy algorithm（ROMA）.